Shaping secondary pharmacology panels of the future: evolving target selection criteria for safety panels
- 22 April 2025
- journal article
- other
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 24 (6) , 482-484
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Enzymes in secondary pharmacology screening panels: is there room for improvement?Nature Reviews Drug Discovery, 2025
- In vitro human ion channel assays predictive of drug-induced seizureToxicological Sciences, 2024
- The state of the art in secondary pharmacology and its impact on the safety of new medicinesNature Reviews Drug Discovery, 2024
- Developing a pragmatic consensus procedure supporting the ICH S1B(R1) weight of evidence carcinogenicity assessmentFrontiers in Toxicology, 2024
- Chronological Analysis of First-in-Class Drugs Approved from 2011 to 2022: Their Technological Trend and OriginPharmaceutics, 2023
- 2000–2023 over two decades of ICH S7A: has the time come for a revamp?Regulatory Toxicology and Pharmacology, 2023
- Safety screening in early drug discovery: An optimized assay panelJournal of Pharmacological and Toxicological Methods, 2019
- Rationalizing Secondary Pharmacology Screening Using Human Genetic and Pharmacological EvidenceToxicological Sciences, 2018
- Potential functional and pathological side effects related to off-target pharmacological activityJournal of Pharmacological and Toxicological Methods, 2017
- Reducing safety-related drug attrition: the use of in vitro pharmacological profilingNature Reviews Drug Discovery, 2012